Argen X SE (ADR) Live Stock Price Today, Share Analysis and Chart

Name: Argen X SE - ADR: Is Infosys Ltd. worth buying?
Item: Argen X SE - ADR
Rating: 1.375236125
Author: Trendlyne DVM scores

Await Turnaround

about

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized mya...

870.55 -7.07 (-0.81%)

56.97% Gain from 52W Low

276.6K

XNAS Volume

XNAS 13 Jul, 2026 2:08 PM (EDT)

Board Meeting

The next board meeting for Argen X SE (ADR) is on 23 Jul 2026 for the purpose of argenx SE Second Quarter Earnings Conference Call for 2026 See details

Low Financial Strength

11.1 / 100

Mid Valuation

31.2 / 100

Technically Neutral

56.6 / 100

Await Turnaround These stocks have poor financials and average valuation and momentum. Investors should be cautious about these stocks View Similar Embed DVM

1,053

1Yr Price target upside is 21%

23 analysts

Argen X SE (ADR) Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Argen X SE (ADR) Live Stock Price Today, Share Analysis and Chart

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized mya...

56.97% Gain from 52W Low

SWOT Analysis

Argen X SE (ADR) Live Price Chart

Argen X SE (ADR) Live Price Chart